Predictors of Treatment Success After Intercostal Nerve Radiofrequency for Intercostal Neuralgia: A Retrospective.

Authors

Kaan Yavuz, Mesut Bakir, Esra Bayburtluoglu, Bedri Ilcan, Nureddin Teker, Sebnem Rumeli

Published in

Pain physician. Volume 29. Issue 6. Pages E671-E677.

Abstract

Intercostal neuralgia, which is characterized by neuropathic pain along the distribution of the intercostal nerves (ICNs), can impair patients' quality of life substantially. ICN-targeted radiofrequency (RF) treatment is used increasingly in current practice; however, data on factors that predict the success of such treatments remain limited.
This study aims to evaluate factors associated with treatment success in patients with intercostal neuralgia who underwent ICN-targeted RF treatment.
A retrospective cohort study.
A single-center retrospective study conducted at Mersin University Faculty of Medicine Hospital.
This retrospective chart review included adults who had post-traumatic, postherpetic, or idiopathic intercostal neuralgia and underwent ultrasound-guided conventional radiofrequency ablation (CRF) or pulsed radiofrequency treatment (PRF) on their ICNs between January 1, 2018, and May 30, 2025. Pain intensity (measured on the NRS-11) was assessed at baseline and at 3 and 6 months after the procedure. The primary outcome was the 6-month treatment response (according to IMMPACT criteria: ≥ 50% pain reduction or a ≥ 4-point decrease in NRS score from its baseline counterpart). Group comparisons and multivariable logistic regression were performed to evaluate the outcomes and predictors of response.
Sixty patients were included in the analysis (CRF, n = 31; PRF, n = 29). At both 3 and 6 months, mean NRS scores were significantly lower in the CRF group than in the PRF group (3 months: 2.77 ± 1.80 vs 5.83 ± 2.55; P < 0.001; 6 months: 2.81 ± 1.93 vs 6.31 ± 2.34; P < 0.001). In the multivariable model, which included age, gender, presence of allodynia, baseline NRS score, and RF modality, only RF modality was identified as an independent predictor of treatment response (OR 9.395; 95% CI 2.363-37.359; P = 0.001).
The single-center setting, relatively small sample size, and retrospective study design.
Ultrasound-guided intercostal CRF may provide clinically meaningful analgesia for patients with refractory intercostal neuralgia. Although both modalities were associated with short-term pain improvement, CRF produced significantly more sustained pain reduction at 3 and 6 months and emerged as the sole independent predictor of treatment success.

PMID:
42804317
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.